JPMorgan initiates Hemab Therapeutics stock with overweight rating

Rodman & Renshaw initiated coverage on Hemab Therapeutics (NASDAQ:COAG) with a buy rating and $56.00 price target, citing potential of sutacimig for Glanzmann thrombasthenia. The company is also developing treatments for Von Willebrand disease. Hemab has a strong balance sheet with a current ratio of 35.85. Recent phase 2 data showed promising results, leading H.C. Wainwright to raise its price target to $60.

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Cong

Hemab Therapeutics (COAG) presented Phase 2 long-term extension data for Sutacimig at ISTH 2026, treating 34 patients with median 6.9 months exposure up to 15.9 months. The company reported an ATBR 92% reduction, manageable safety, and FDA alignment to move to Phase 3 with a weekly regimen. Wedbush reiterated Outperform and a $55 target.

Hemab Therapeutics (Nasdaq:COAG) reported Phase 2 long-term extension data for sutacimig in Glanzmann thrombasthenia and preclinical results in Factor VII deficiency at ISTH 2026. In 34 patients (median 6.9 months, up to 15.9), treated bleed rates fell, with no Grade 3+ related AEs. FDA endorsed a 0.2 mg/kg Q1 week Phase 3 plan in 2H 2026.

Hemab Therapeutics (NASDAQ:COAG) reported early clinical and pharmacology findings for HMB-002 in von Willebrand disease, saying a single 150 mg subcutaneous dose increased VWF and FVIII by at least 2.4-fold, supported thrombin generation, and showed mild to moderate adverse events. The company also introduced HMB-003 for heavy menstrual bleeding. COAG shares were up 6.42% to $40.47.

Hemab Therapeutics (Nasdaq:COAG) reported new HMB-002 clinical data for von Willebrand disease at ISTH 2026, citing dose-dependent increases of VWF and FVIII, including ≥2.4-fold peaks in cohort A3 (150 mg), plus normalization of thrombin generation and APTT. It also announced HMB-003, a non-hormonal plasmin inhibitor targeting heavy menstrual bleeding.